Pharma Stock Roundup: Mixed Q1 For MRK, PFE, FDA Nod For Kymriah&
First-quarter results of pharma bigwigs like Pfizer PFE, Merck MRK and Allergan AGN stole the limelight this week. Other than that, Novartis NVS gained FDA approval for the second indication of its CAR-T therapy, Kymriah. While AbbVie ABBV submitted a regulatory application in the EU for its psoriasis candidate, risankizumab, Merck’s PD-L1 inhibitor, Keytruda gained FDA’s Priority Review status for yet another label expansion…